1-12 of 12
John Wright
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Free
Laleh Amiri-Kordestani, Victoria Luchenko, Cody J. Peer, Kambiz Ghafourian, James Reynolds, Deb Draper, Robin Frye, Sue Woo, David Venzon, John Wright, Monica Skarulis, William D. Figg, Tito Fojo, Susan E. Bates, Richard L. Piekarz
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4499–4507.
https://doi.org/10.1158/1078-0432.CCR-13-0095
Published: 13 August 2013
View articletitled, Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Open the PDF for Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Free
Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, Martha D. Wellons, Heidi Sankala, Austin Doyle, John Wright, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1873–1883.
https://doi.org/10.1158/1078-0432.CCR-12-2926
Published: 02 April 2013
View articletitled, A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Open the PDF for A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms

Free
Beata Holkova, E. Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Ellen Shrader, Neha Talreja, Martha D. Wellons, Kevin T. Hogan, G. David Roodman, Domenico Coppola, Loveleen Kang, Jana Dawson, Robert K. Stuart, Cody Peer, William D. Figg, Sr., Sarah Kolla, Austin Doyle, John Wright, Daniel M. Sullivan, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3388–3397.
https://doi.org/10.1158/1078-0432.CCR-10-2876
Published: 15 May 2011
View articletitled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-Cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes

Free
Owen A. O'Connor, Carol Portlock, Craig Moskowitz, Paul Hamlin, David Straus, John Gerecitano, Mithat Gonen, Otilia Dumitrescu, Debra Sarasohn, John Butos, Ellen Neylon, Barbara Mac-Gregor Cortelli, Susan Blumel, Andrew M. Evens, Andrew D. Zelenetz, John Wright, Brenda Cooper, Jane Winter, Julie Vose
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 719–726.
https://doi.org/10.1158/1078-0432.CCR-08-2647
Published: 14 January 2010
View articletitled, Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes
Open the PDF for Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes in another window
Journal Articles

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Free
Olatoyosi M. Odenike, Serhan Alkan, Dorie Sher, John E. Godwin, Dezheng Huo, Stephen J. Brandt, Margaret Green, Jingping Xie, Yanming Zhang, David H. Vesole, Patrick Stiff, John Wright, Richard A. Larson, Wendy Stock
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7095–7101.
https://doi.org/10.1158/1078-0432.CCR-08-1007
Published: 03 November 2008
View articletitled, Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia
Open the PDF for Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia in another window
Journal Articles

A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study

Free
Terzah M. Horton, Debananda Pati, Sharon E. Plon, Patrick A. Thompson, Lisa R. Bomgaars, Peter C. Adamson, Ashish M. Ingle, John Wright, Adam H. Brockman, Martin Paton, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1516–1522.
https://doi.org/10.1158/1078-0432.CCR-06-2173
Published: 01 March 2007
View articletitled, A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study
Open the PDF for A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study in another window
Journal Articles

Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group

Free
Robert Gray, Judith Manola, Scott Saxman, John Wright, Jan Dutcher, Michael Atkins, Michael Carducci, William See, Christopher Sweeney, Glenn Liu, Mark Stein, Robert Dreicer, George Wilding, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 1966–1969.
https://doi.org/10.1158/1078-0432.CCR-05-1136
Published: 11 April 2006
View articletitled, Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group
Open the PDF for Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group in another window
Journal Articles

A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer

Free
Helen Mackay, David Hedley, Pierre Major, Carol Townsley, Mary Mackenzie, Mark Vincent, Pam Degendorfer, Ming-Sound Tsao, Trudey Nicklee, Diana Birle, John Wright, Lillian Siu, Malcolm Moore, Amit Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5526–5533.
https://doi.org/10.1158/1078-0432.CCR-05-0081
Published: 01 August 2005
View articletitled, A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer
Open the PDF for A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer in another window
Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors

Free
Vali Papadimitrakopoulou, Sofia Agelaki, Hai T. Tran, Merrill Kies, Robert Gagel, Ralph Zinner, Edward Kim, Gregory Ayers, John Wright, Fadlo Khuri
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (11): 4151–4159.
https://doi.org/10.1158/1078-0432.CCR-04-1659
Published: 01 June 2005
View articletitled, Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors
Open the PDF for Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors in another window
Journal Articles

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

Free
Manisha H. Shah, Donn Young, Hedy L. Kindler, Iain Webb, Barbara Kleiber, John Wright, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6111–6118.
https://doi.org/10.1158/1078-0432.CCR-04-0422
Published: 24 September 2004
View articletitled, Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

State of the Translational Science: Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003

Free
Arthur Zelent, Samuel Waxman, Michael Carducci, John Wright, James Zweibel, Steven D. Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (14): 4622–4629.
https://doi.org/10.1158/1078-0432.CCR-1219-03
Published: 21 July 2004
View articletitled, State of the Translational Science: Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003
Open the PDF for State of the Translational Science: Summary of Baltimore Workshop on Gene Re-expression As a Therapeutic Target in Cancer January 2003 in another window
Journal Articles

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Free
Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3371–3376.
https://doi.org/10.1158/1078-0432.CCR-03-0508
Published: 24 May 2004
View articletitled, Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Open the PDF for Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias in another window